https://mindmedicinelaw.com/briefing/optimi-health-s-mdma-production-milestone-phase-3-ptsd-trial-supply-in-focus-20261020-52190The Psychedelic Journalen2026-10-20T22:04:18.464853+00:00Optimi Health’s MDMA Production Milestone: Phase 3 PTSD Trial Supply in Focusmdma production, optimi health, phase 3 ptsd trial, gmp manufacturing, psychedelic research, clinical trial supply, health canada, fda regulation, ptsd treatment research, controlled substanceshttps://mindmedicinelaw.com/briefing/mdma-supply-milestone-optimi-health-supports-phase-3-trials-in-canada-israel-and-20261020-52026The Psychedelic Journalen2026-10-20T15:06:46.405409+00:00MDMA Supply Milestone: Optimi Health Supports Phase 3 Trials in Canada, Israel, and Australiamdma supply chain, optimi health, phase 3 clinical trials, ptsd treatment research, canada psychedelic regulation, israel maps trial, australia mdma commercial use, gmp pharmaceutical standards, psychedelic medicine infrastructurehttps://mindmedicinelaw.com/briefing/pharma-s-accelerated-push-for-ketamine-therapies-in-the-u-s-20261020-52029The Psychedelic Journalen2026-10-20T15:06:25.663973+00:00Pharma’s Accelerated Push for Ketamine Therapies in the U.S.ketamine commercialization, pharmaceutical industry, psychedelic research, FDA regulation, intellectual property, clinical trials, mental health policy, access to treatment, payer coverage, US healthcarehttps://mindmedicinelaw.com/briefing/dms-cp-ampars-and-aversion-resistant-alcohol-use-insights-for-addiction-neurosci-20261019-51960The Psychedelic Journalen2026-10-20T15:08:56.379453+00:00DMS CP-AMPARs and Aversion-Resistant Alcohol Use: Insights for Addiction Neurosciencedorsomedial striatum, calcium-permeable ampa receptors, aversion-resistant drinking, alcohol use disorder, synaptic plasticity, addiction neuroscience, preclinical mouse study, psychedelic research, glutamatergic signalinghttps://mindmedicinelaw.com/briefing/mdma-for-ptsd-evidence-policy-and-perception-in-the-u-s-20261019-52028The Psychedelic Journalen2026-10-20T15:08:35.171052+00:00MDMA for PTSD: Evidence, Policy, and Perception in the U.S.mdma, ptsd, fda approval, psychedelic therapy, clinical trials, drug policy, media influence, safety risks, maps pbc, dea schedulinghttps://mindmedicinelaw.com/briefing/ketamine-for-ocd-rapid-relief-short-duration-in-clinical-review-20261019-51959The Psychedelic Journalen2026-10-20T15:07:29.960608+00:00Ketamine for OCD: Rapid Relief, Short Duration in Clinical Reviewketamine, obsessive-compulsive disorder, OCD, neuroplasticity, clinical trials, NMDA receptor, adjunctive therapy, treatment-resistant OCD, psychopharmacology, regulatory policyhttps://mindmedicinelaw.com/briefing/product-specific-safety-evidence-for-cannabis-and-psilocybe-regulatory-and-clini-20261019-51947The Psychedelic Journalen2026-10-20T15:07:14.001412+00:00Product-Specific Safety Evidence for Cannabis and Psilocybe: Regulatory and Clinical Implicationsproduct-specific safety, cannabis regulation, psilocybe clinical trials, evidence extrapolation, botanical drug quality, claim-linked record, psychedelic research, regulatory standards, clinical safety, cannabinoid contenthttps://mindmedicinelaw.com/briefing/esketamine-vs-ketamine-clinical-and-policy-distinctions-in-u-s-psychiatric-care-20261019-51707The Psychedelic Journalen2026-10-19T15:05:22.233058+00:00Esketamine vs. Ketamine: Clinical and Policy Distinctions in U.S. Psychiatric Careesketamine, ketamine, fda approval, off-label use, psychiatric care, insurance coverage, clinical trials, prescriber liability, remS program, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/dea-considers-ncnpr-s-bid-to-manufacture-psychedelic-substances-20261019-51578The Psychedelic Journalen2026-10-19T15:04:46.526739+00:00DEA Considers NCNPR's Bid to Manufacture Psychedelic Substancesdea registration, ncnpr, controlled substances, psychedelic research, university of mississippi, bulk manufacturing, clinical trials, research supply chain, policy implications, federal registerhttps://mindmedicinelaw.com/briefing/phenomenological-taxonomies-in-psychedelic-research-insights-from-yoga-v-si-ha-20261018-51916The Psychedelic Journalen2026-10-20T15:07:54.824212+00:00Phenomenological Taxonomies in Psychedelic Research: Insights from Yoga Vāsiṣṭhaphenomenological taxonomy, psychedelic research, hypnosis, yoga vāsiṣṭha, altered states, clinical trial design, fundamental peace, csst model, mystical experience, emotional regulationhttps://mindmedicinelaw.com/briefing/psilocybin-s-antidepressant-durability-new-evidence-from-year-long-follow-up-20261018-51708The Psychedelic Journalen2026-10-19T15:05:04.599325+00:00Psilocybin’s Antidepressant Durability: New Evidence from Year-Long Follow-Uppsilocybin, depression, clinical trial, placebo, long-term efficacy, psychedelic therapy, FDA, maintenance dosing, integration support, mental health policyhttps://mindmedicinelaw.com/briefing/dea-and-iowa-approve-ayahuasca-import-for-psychedelic-church-20261017-52027The Psychedelic Journalen2026-10-20T15:05:58.730960+00:00DEA and Iowa Approve Ayahuasca Import for Psychedelic Churchayahuasca, dea approval, iowa drug policy, psychedelic church, religious exemption, entheogenic access, schedule i substances, drug import permits, rfra, psychedelic lawhttps://mindmedicinelaw.com/briefing/meditation-and-substance-use-alcohol-cannabis-and-psychedelics-in-practice-20261017-51595The Psychedelic Journalen2026-10-19T15:05:41.968978+00:00Meditation and Substance Use: Alcohol, Cannabis, and Psychedelics in Practicemeditation and substance use, polysubstance use, psychedelics, alcohol and meditation, cannabis, harm reduction, well-being outcomes, psychedelic exceptionalism, public health, behavioral interventionshttps://mindmedicinelaw.com/briefing/psilocybin-s-therapeutic-potential-depression-pain-and-inflammation-20261014-51924The Psychedelic Journalen2026-10-20T15:09:16.468462+00:00Psilocybin’s Therapeutic Potential: Depression, Pain, and Inflammationpsilocybin, depression, chronic pain, inflammation, narrative review, default mode network, clinical trial design, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/colorado-springs-police-target-unregulated-psilocybin-thc-sales-20261014-52030The Psychedelic Journalen2026-10-20T15:08:16.267324+00:00Colorado Springs Police Target Unregulated Psilocybin, THC Salescolorado springs, psilocybin enforcement, thc sales raids, psychedelic law, state vs local regulation, proposition 122, compliance risk, decriminalization, gray market